Modern immunoprophylaxis of chronic inflammatory diseases of the genitourinary system: a systematic data review

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The review presents a comprehensive analysis of the use of bacterial lysate Uro-Vaxom® in the prevention of recurrent lower urinary tract infections. The molecular mechanisms of action of the drug based on the activation of both innate and adaptive immunity through interaction with Toll-like receptors are considered. The data of clinical studies confirming the efficacy and safety of the drug are systematized, which is reflected in Russian clinical guidelines [1] and patient management protocols approved by the Ministry of Health of the Russian Federation and the Russian Society of Urologists. Particular attention is paid to other promising areas of drug use in patients with neurogenic bladder dysfunction and chronic prostatitis. The results of new experimental studies demonstrating the absence of cytotoxicity and a standardized composition of the drug are presented. The uniqueness of the review lies in the integration of the latest data from fundamental and clinical studies, including ongoing phase 4 trials, which allows for a comprehensive assessment of the drug’s potential as an alternative to long-term antibiotic prophylaxis in the context of growing antibiotic resistance. The analysis also noted the important role of immunoprophylaxis in pregravid preparation and during pregnancy. The safety and efficacy of E. coli bacterial lysate in reducing urinary tract infection recurrence were assessed.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Apolikhina

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: apolikhina@inbox.ru
ORCID iD: 0000-0002-4581-6295

Dr. Sci. (Med.), Professor, Honored Doctor of the Russian Federation, Head of the Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductive Medicine, Institute of Postgraduate Education, I.M. Sechenov First Moscow State Medical University (Sechenov University); Professor at the Department of Obstetrics and Gynecology, Department of Professional Education, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Ресей, Moscow; Moscow

Muhaned Arfa

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Хат алмасуға жауапты Автор.
Email: arfamouhaned@yandex.ru
ORCID iD: 0009-0007-4966-6830

Obstetrician-Gynecologist, Postgraduate Student at the Department of Obstetrics, Gynecology, Perinatology and Reproductive Medicine, Institute of Postgraduate Education

Ресей, Moscow

T. Teterina

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Email: palpebra@inbox.ru
ORCID iD: 0000-0003-0990-2302

Cand. Sci. (Med.), Obstetrician-Gynecologist, Ultrasonographer at the Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Expert of the Association of Specialists in Aesthetic Gynecology (ASEG)

Ресей, Moscow

Әдебиет тізімі

  1. Клинические рекомендации «Цистит у женщин». М., 2024. [Clinical Recommendations for Cystitis in Women. M., 2024. (In Russ.)].
  2. EAU Guidelines on Urological Infections 2025 [Internet]. Arnhem, The Netherlands: European Association of Urology, 2025 (cited 2025 Apr 28). URL: https://uroweb.org/guidelines/urological-infections
  3. Мигачева Н.Б. Рецидивирующие инфекции нижних мочевых путей: иммунологические аспекты патогенеза, лечения и профилактики рецидивов. Эффективная фармакотерапия. 2022;18(37):42–54. [Migacheva N.B. Recurrent lower urinary tract infections: immunological aspects of pathogenesis, treatment and prevention of relapses. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2022;18(37):42–54.
  4. Гамидов С.И., Шатылко Т.В., Гасанов Н.Г. Подходы к профилактике рецидивов инфекций мочевыводящих путей у небеременных женщин. Русский медицинский журнал. 2019;4:72–5. [Gamidov S.I., Shatylko T.V., Gasanov N.G. Approaches to the prevention of recurrent urinary tract infections in non-pregnant women. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2019;4:72–5. (In Russ.)].
  5. Aggarwal N., Leslie S.W. Recurrent Urinary Tract Infections [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 (cited 2025 Feb. 22). URL: http://www.ncbi.nlm.nih.gov/books/NBK557479
  6. Wagenlehner F.M.E., Bjerklund Johansen T.E., Cai T., et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17:586–600.
  7. Зайцев А.В., Ширяев А.А., Ким Ю.А. и др. Инфекции мочевыводящих путей. Современная тактика врача-уролога. Русский медицинский журнал. 2019;11:21–6. [Zaitsev A.V., Shiryaev A.A., Kim Yu.A., et al. Urinary tract infections. Modern tactics of a urologist. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2019;11:21–6. (In Russ.)].
  8. Zhou Y., Zhou Z., Zheng L., et al. Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options. Int J Mol Sci. 2023;24(13):10537.
  9. Ansaldi Y., Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023;29(10):1249–53. doi: 10.1016/j.cmi.2022.08.015
  10. Стуров Н.В., Попов С.В., Лесная О.А. Этиотропная терапия острого цистита у беременных. Антибиотики и химиотерапия. 2019;7–8. [цитировано 2025 апр 27]. [Sturov N.V., Popov S.V., Lesnaya O.A. Etiotropic therapy of acute cystitis in pregnant women. Antibiot. Chemother. 2019;7–8. [cited 2025 Apr 27]. (In Russ.)]. URL: https://cyberleninka.ru/article/n/etiotropnaya-terapiya-ostrogo-tsistita-u-beremennyh
  11. Mak Q., Greig J., Dasgupta P., et al. Bacterial vaccines for the management of recurrent urinary tract infections: a systematic review and meta-analysis. Eur Urol Focus. 2024;10(5):761–9.
  12. Barea B.M., Veeratterapillay R., Harding C. Nonantibiotic treatments for urinary cystitis: an update. Curr Opin Urol. 2020;30(6):845–52.
  13. Song G., Koro M., Leung V., Loh G. Literature review of ascorbic acid, cranberry, and D-mannose for urinary tract infection prophylaxis in older people. Senior Care Pharmacist. 2023;38(8):315–28.
  14. Abdelghani Z., Hourani N., Zaidan Z., et al. Therapeutic applications and biological activities of bacterial bioactive extracts. Arch Microbiol. 2021;203:4755–76.
  15. Yang B., Foley S. Urinary tract infection vaccines – the ‘burning’ issue. BJU International. 2019. https://dx.doi.org/10.1111/bju.14678.
  16. Красняк С.С. Неантибактериальная терапия и профилактика острого и рецидивирующего цистита: существующие варианты и перспективы. Экспериментальная и клиническая урология. 2020;1:96–103. [Krasnyak S.S. Non-antibacterial therapy and prevention of acute and recurrent cystitis: existing options and prospects. Exp Clin Urol. 2020;1:96–103. (In Russ.)].
  17. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract – influence of physiological, pathophysiological and pharmaceutical factors. Front. Pharmacol. 2020;11:524.
  18. Escherichia Coli Vaccine. Current Opinion in Immunology. 2023.
  19. Schmidhammer S., Ramoner R., Höltl L., et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002;60:521–6.
  20. Huber M., Krauter K., Winkelmann G., et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol. 2000;22:1103–11.
  21. Ahumada-Cota R.E., Hernandez-Chiñas U., Milián-Suazo F., et al. Effect and analysis of bacterial lysates for the treatment of recurrent urinary tract infections in adults. Pathogens. 2020;9(2):102.
  22. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol. 2000;22:57–68.
  23. Ахматова Н.К., Хоменков В.Г., Волкова Е.В. и др. Бактериальные лизаты Escherichia coli стимулируют продукцию дефенсинов нейтрофилами периферической крови. Иммунология. 2020;4:312–20. [Akhmatova N.K., Khomenkov V.G., Volkova E.V., et al. Bacterial lysates of Escherichia coli stimulate the production of defensins by peripheral blood neutrophils. Immunology. 2020;4:312–20. (In Russ.)].
  24. Ohto U. Activation and regulation mechanisms of NOD-like receptors based on structural biology. Front Immunol. 2022;13:953530.
  25. Brodie A., El-Taji O., Jour I., et al. A retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89®) for prophylaxis of recurrent urinary tract infections. Curr Urol. 2020;14(3):130–4.
  26. Acevedo-Monroy S.E., Rocha-Ramírez L.M., Martinez Gomez D., et al. Polyvalent bacterial lysate with potential use to treatment and control of recurrent urinary tract infections. Int J Mol Sci. 2024;25:6157.
  27. Ciudin A., Padulles B., Popescu R., Manasia P. Autovaccine-based immunotherapy: a promising approach for male recurrent urinary tract infections. Life. 2024;14:111.
  28. Зайцев А.В., Перепанова Т.С., Гвоздев М.Ю., Арефьева О.А. Инфекции мочевыводящих путей. Ч. 1: методические рекомендации № 57. М., 2017. 32 с. [Zaitsev A.V., Perepanova T.S., Gvozdev M.Yu., Arefyeva O.A. Urinary tract infections. Part 1: methodological recommendations No. 57. M., 2017. 32 p. (In Russ.)].
  29. Bonkat G., Pickard R., Bartoletti R., et al. EAU Guidelines on Urological Infections. Arnhem: European Association of Urology; 2017. 64 p.
  30. AdzuPharma. Phase 4 study of OM-89 in Chronic Prostatitis/Chronic Pelvic Pain Syndrome [Electronic resource]. ClinicalTrials.gov; 2024 [cited 2025 Feb 22]. URL: https://clinicaltrials.gov/study/NCT06345014.
  31. Ghouri F., Hollywood A., Ryan K. A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy. BMC. Pregnancy Childbirth. 2018;18(1):99. https://dx.doi.org/10.1186/s12884-018-1732-2
  32. Baertschi R., Balmer J., Eduah S., et al. Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2003;14(5):333–7.
  33. Grischke E.M., Ruttgers H. Efficacy of bacterial lysate in the treatment of recurrent urinary tract infections in pregnancy. Geburtshilfe Frauenheilkd. 1992;52(9):535–8.
  34. Park S.J., Byun D.O., Shim B.S. The Application of Uro-vaxom(R), Urinary Tract Immunostimulator in the Treatment of Chronic Pelvic Pain Syndrome. Korean J Urol. 2005;46(8):810–814.
  35. Lee H.N., Kim J.S., Shim B.S. The Recurrence of Chronic Pelvic Pain Syndrome and the Role of Uro-Vaxom®. Korean J Urol. 2006 Jan;47(1):42–46. https://doi.org/10.4111/kju.2006.47.1.42

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025